Osimertinib has been shown to be useful in patients with early stage non-small cell lung cancer (NSCLC) with resectable disease, according to a ‘practice-changing’ presentation at the 2020 ASCO Virtual Scientific Program. Professor Roy Herbst, chief of medical oncology from Yale Cancer Centre, said the findings built on the known efficacy and safety of the ...
Osimertinib may be new standard of care in early stage NSCLC
By Mardi Chapman
2 Jun 2020